Bamlanivimab plus etesevimab in mild or moderate Covid-19
…, DR Patel, MC Dabora, P Klekotka… - … England Journal of …, 2021 - Mass Medical Soc
Background Patients with underlying medical conditions are at increased risk for severe
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, …
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, …
Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial
…, NL Kallewaard, J Sabo, DR Patel, P Klekotka… - Jama, 2021 - jamanetwork.com
Importance Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide.
Neutralizing antibodies are a potential treatment for COVID-19. Objective To determine the …
Neutralizing antibodies are a potential treatment for COVID-19. Objective To determine the …
SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19
…, J Sabo, DR Patel, P Klekotka… - … England Journal of …, 2021 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes
coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-…
coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-…
[HTML][HTML] Phase 3 studies comparing brodalumab with ustekinumab in psoriasis
…, CE Milmont, Y Shi, N Erondu, P Klekotka… - … England Journal of …, 2015 - Mass Medical Soc
Background Early clinical studies suggested that the anti–interleukin-17 receptor A monoclonal
antibody brodalumab has efficacy in the treatment of psoriasis. Methods In two phase 3 …
antibody brodalumab has efficacy in the treatment of psoriasis. Methods In two phase 3 …
Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8α+ conventional dendritic cells
…, M Kohyama, LA Benoit, PA Klekotka… - Journal of Experimental …, 2010 - rupress.org
Although CD103-expressing dendritic cells (DCs) are widely present in nonlymphoid tissues,
the transcription factors controlling their development and their relationship to other DC …
the transcription factors controlling their development and their relationship to other DC …
[HTML][HTML] The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings
DA Martin, JE Towne, G Kricorian, P Klekotka… - Journal of Investigative …, 2013 - Elsevier
Although the histological changes seen in psoriasis have long been well characterized, the
underlying cellular and molecular mechanisms have only begun to be elucidated over the …
underlying cellular and molecular mechanisms have only begun to be elucidated over the …
Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial
…, J Knorr, KL Price, J Sabo, JL Tuttle, P Klekotka… - Jama, 2021 - jamanetwork.com
Importance Preventive interventions are needed to protect residents and staff of skilled
nursing and assisted living facilities from COVID-19 during outbreaks in their facilities. …
nursing and assisted living facilities from COVID-19 during outbreaks in their facilities. …
A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease
…, Y Chon, YH Hsu, SL Lin, P Klekotka - Official journal of the …, 2016 - journals.lww.com
… Paul Klekotka: study design, data analysis and interpretation, and drafting of manuscript. All
… Hsu, Shao-Lee Lin, and Paul Klekotka were/are employees and stockholders of Amgen. The …
… Hsu, Shao-Lee Lin, and Paul Klekotka were/are employees and stockholders of Amgen. The …
[HTML][HTML] Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn's disease: a phase 2a study
…, P Newbold, R Faggioni, K Patra, J Li, P Klekotka… - Gastroenterology, 2017 - Elsevier
Background & Aims MEDI2070 is a human monoclonal antibody that selectively inhibits
interleukin 23 (IL23), a cytokine implicated in the pathogenesis of Crohn’s disease (CD). We …
interleukin 23 (IL23), a cytokine implicated in the pathogenesis of Crohn’s disease (CD). We …
[HTML][HTML] Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis
…, E Berliba, BG Feagan, T Hibi, JL Tuttle, P Klekotka… - Gastroenterology, 2020 - Elsevier
Background & Aims Interleukin 23 contributes to the pathogenesis of ulcerative colitis (UC).
We investigated the effects of mirikizumab, a monoclonal antibody against the p19 subunit of …
We investigated the effects of mirikizumab, a monoclonal antibody against the p19 subunit of …
